Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-19T06:39:25.009Z Has data issue: false hasContentIssue false
  • English
  • Français

Predicting memory decline as a risk factor for Alzheimer's disease in older post-menopausal women: quod erat demonstrandum?

Published online by Cambridge University Press:  09 October 2009

Mark A. Rodrigues ,
Jonathan K. Foster ,
Giuseppe Verdile ,
Karen Joesbury ,
Richard Prince ,
Amanda Devine ,
Pankaj Mehta ,
John Beilby  and
Ralph N. Martins
Mark A. Rodrigues
Affiliation:
Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital; Centre of Excellence in Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Western Australia; and School of Psychiatry and Clinical Neurosciences, University of Western Australia, Australia
Jonathan K. Foster
Affiliation:
Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital; Centre of Excellence in Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Western Australia; and School of Psychiatry and Clinical Neurosciences, University of Western Australia, Australia Neurosciences Unit, Health Department of WA, Perth, Western Australia, Australia Email: [email protected]
Giuseppe Verdile
Affiliation:
Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital; Centre of Excellence in Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Western Australia; and School of Psychiatry and Clinical Neurosciences, University of Western Australia, Australia
Karen Joesbury
Affiliation:
Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital; Centre of Excellence in Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Western Australia; and School of Psychiatry and Clinical Neurosciences, University of Western Australia, Australia
Richard Prince
Affiliation:
School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, University of Western Australia and Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Western Australian Institute for Medical Research, Western Australia, Australia
Amanda Devine
Affiliation:
School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
Pankaj Mehta
Affiliation:
Institute for Basic Research in Developmental Disabilities, New York, U.S.A.
John Beilby
Affiliation:
PathCentre, Western Australian Centre for Pathology and Medical Research, Clinical Biochemistry, Nedlands, Western Australia, Australia
Ralph N. Martins
Affiliation:
Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital; Centre of Excellence in Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Western Australia; and School of Psychiatry and Clinical Neurosciences, University of Western Australia, Australia
Rights & Permissions [Opens in a new window]

Extract

Alzheimer's disease (AD) is the major form of age-related dementia worldwide, accounting for more than two-thirds of all dementia cases. The disease is characterized by a progressive loss of cognitive and intellectual functioning (Gilman, 1997). A number of risk factors for AD have been identified. The prevalence of AD increases with age, diabetes, depression, family history of Parkinson's disease and following head injury or exposure to solvents (Jorm et al., 1991; van Duijn et al., 1991; Ott et al., 1995; Yoshitake et al., 1995; Devanand et al., 1996). Published research further suggests that low education levels are associated with increased prevalence of clinical AD (Gatz et al., 2001; Qiu et al., 2001; Ravaglia et al., 2002). Women also have a higher risk for developing the disease than men, with the risk being markedly increased following menopause (Sherwin, 2002; Sherwin 2003). Additionally, slightly more severe cognitive deficits have been reported in AD in women compared to men (Buckwalter et al., 1993, Henderson and Buckwalter, 1994). These epidemiological trends may be a consequence of reproductive hormonal changes. Specifically, menopause results in a marked diminution in gonadal estrogen production in women (see Sherwin, 2003, for a review). Estrogen plays a pivotal role in the maintenance and function of neuronal circuits in the brain and in resistance to neuronal damage (McEwen, 2001). The neuroprotective properties of estrogen are thought to be mediated at least in part by anti-amyloidogenic, anti-oxidative and ant-inflammatory mechanisms (reviewed in Barron et al., 2006a). However, limited and somewhat mixed data exist regarding the association between endogenous levels of estrogen and cognitive decline (Manly et al., 2000; Schupf et al., 2003). Based on some of our own findings, we here consider the factors that may be useful in predicting memory decline as a risk factor for Alzheimer's disease in older post-menopausal women.

Type
Letters
Information
International Psychogeriatrics , Volume 22 , Issue 2 , March 2010 , pp. 332 - 335
Copyright
Copyright © International Psychogeriatric Association 2009

Alzheimer's disease (AD) is the major form of age-related dementia worldwide, accounting for more than two-thirds of all dementia cases. The disease is characterized by a progressive loss of cognitive and intellectual functioning (Gilman, Reference Gilman1997). A number of risk factors for AD have been identified. The prevalence of AD increases with age, diabetes, depression, family history of Parkinson's disease and following head injury or exposure to solvents (Jorm et al., Reference Jorm1991; van Duijn et al., Reference van Duijn, Stijnen and Hofman1991; Ott et al., Reference Ott1995; Yoshitake et al., Reference Yoshitake1995; Devanand et al., Reference Devanand1996). Published research further suggests that low education levels are associated with increased prevalence of clinical AD (Gatz et al., Reference Gatz, Svedberg, Pedersen, Mortimer, Berg and Johansson2001; Qiu et al., Reference Qiu, Backman, Winblad, Aguero-Torres and Fratiglioni2001; Ravaglia et al., Reference Ravaglia2002). Women also have a higher risk for developing the disease than men, with the risk being markedly increased following menopause (Sherwin, Reference Sherwin2002; Sherwin Reference Sherwin2003). Additionally, slightly more severe cognitive deficits have been reported in AD in women compared to men (Buckwalter et al., Reference Buckwalter, Sobel, Dunn, Diz and Henderson1993, Henderson and Buckwalter, Reference Henderson and Buckwalter1994). These epidemiological trends may be a consequence of reproductive hormonal changes. Specifically, menopause results in a marked diminution in gonadal estrogen production in women (see Sherwin, Reference Sherwin2003, for a review). Estrogen plays a pivotal role in the maintenance and function of neuronal circuits in the brain and in resistance to neuronal damage (McEwen, Reference McEwen2001). The neuroprotective properties of estrogen are thought to be mediated at least in part by anti-amyloidogenic, anti-oxidative and ant-inflammatory mechanisms (reviewed in Barron et al., Reference Barron, Fuller, Verdile and Martins2006a). However, limited and somewhat mixed data exist regarding the association between endogenous levels of estrogen and cognitive decline (Manly et al., Reference Manly2000; Schupf et al., Reference Schupf2003). Based on some of our own findings, we here consider the factors that may be useful in predicting memory decline as a risk factor for Alzheimer's disease in older post-menopausal women.

We have previously noted the relationship between reproductive hormones (estrogen, leutinizing hormone (LH) and follicle stimulating hormone (FSH)) and global cognitive status in a large cohort of over 500 postmenopausal women (Rodrigues et al., Reference Rodrigues2008). However, with respect to the symptomatology of early stage AD, specific deficits in episodic learning and memory are the most commonly occurring cognitive signs of the disease (Collie and Maruff, Reference Collie and Maruff2000; Remy et al., Reference Remy, Mirrashed, Campbell and Richter2005). We have noted a lack of independent or combined association between endogenous estrogen status and episodic memory capacity in the same cohort of over 500 older postmenopausal women studied by Rodrigues et al. (Reference Rodrigues2008). This finding was observed despite the fact that the relatively large dataset allowed for the application of powerful statistical techniques, specifically with respect to multiple linear regression. This outcome is consistent with our previous report (Rodrigues et al., Reference Rodrigues2008) that estrogen did not have a statistically significant impact on global cognitive status in the same cohort; instead, gonadotropins, LH and FSH showed significant associations with global cognition. Further, gonadotropins have been reported to exert a significant role in AD risk and pathogenesis (reviewed in Barron et al., Reference Barron, Verdile and Martins2006b). However, in contrast to our findings, other studies have reported that endogenous estrogen does exert a significant effect on cognition (Drake et al., Reference Drake2000; Senanarong et al., Reference Senanarong2002; Wolf and Kirschbaum, Reference Wolf and Kirschbaum2002; Yaffe et al., Reference Yaffe, Lui, Grady, Cauley, Kramer and Cummings2000), and that estrogen shows no associations with gonadotropin levels (Hoskin et al., Reference Hoskin, Tang, Manly and Mayeux2004; Tsolaki et al., Reference Tsolaki2005). The discrepancies that exist in these studies merit further consideration, specifically with respect to issues concerning sample size, age of cohort, presence of other AD-associated risk factors (including the APOE ϵ4 allele) and the type of cognitive capacity being evaluated.

A specific threshold for estrogen may exist in relation to its influence on cognition: it is possible that clinically measurable effects of estrogen on cognition may only occur at higher concentrations (for example, after exogenous estrogen administration), compared with levels that are naturally present in post-menopausal women. In this context, it is relevant that several studies using measures of episodic memory have found an improvement in cognitive performance after exogenous estrogen replacement therapy (Phillips and Sherwin, Reference Phillips and Sherwin1992; Kampen and Sherwin, Reference Kampen and Sherwin1994; Jacobs et al., Reference Jacobs1998; Burkhardt et al., Reference Burkhardt2004). Indeed, considering the substantial number of investigations into the effects of estrogen administration on memory in post-menopausal women, it is perhaps surprising that relatively little evidence exists concerning the relationship between endogenous estrogen concentration and episodic memory. Exogenous treatments of estrogen in post-menopausal women may better match the naturally occurring biological levels found in pre-menopausal women, and may be more likely to have a significant impact on memory and learning. Further, given that the findings the we note here were obtained in a relatively older cohort (aged 75–86 years; Rodrigues et al., Reference Rodrigues2008), it is possible that women's endogenous estrogen levels in the earlier post-menopause years are more strongly associated with episodic memory functioning.

We further observed in this cohort (Rodrigues et al., Reference Rodrigues2008) that the possession of an APOE ϵ4 allele did not have a statistically significant impact on verbal episodic memory performance. This finding is again consistent with our previous investigation of global cognitive status in this cohort of older post-menopausal women (Rodrigues et al., Reference Rodrigues2008). This point notwithstanding, considerable empirical evidence exists regarding the APOE genotype and its role in modifying the risk of age-related cognitive decline and AD. However, the presence of the ϵ4 allele is associated with less than 50% of the population of patients with AD (Evans et al., Reference Evans1997). Furthermore, this allele may not be a significant risk factor in all ethnic groups (Evans et al., Reference Evans2003). In this cohort of post-menopausal women, other modulating factors such as education, age and other relevant biomarkers may have attenuated the impact of APOE genotype. We believe that this issue also warrants further discussion and investigation.

Elderly people have an enhanced risk of depressive disorders and symptoms (Wells et al., Reference Wells1989; Judd and Akiskal, Reference Judd and Akiskal2000; Judd et al., Reference Judd2000). Moreover, a number of studies have reported a potentially important link between age-related depression and memory decline (Kral, Reference Kral1983; Alexopoulos et al., Reference Alexopoulos, Young and Meyers1993; Devanand et al., Reference Devanand1996). In our cohort (Rodrigues et al., Reference Rodrigues2008), depression was found not to be a significant factor associated with episodic learning or memory performance. The existing literature suggests that symptoms of depression can have quite specific effects on elements of cognitive functioning. This consideration might be highly relevant in this context.

Our data were consistent with established findings linking increased age, reduced educational level and increased blood-borne beta amyloid to lower episodic memory capacity. Further, one element of memory capacity that was evaluated (delayed recognition performance) was significantly associated with statin use and with hypertension status in this cohort (Rodrigues et al., Reference Rodrigues2008). Statins are used as pharmaceutical agents to reduce plasma levels of cholesterol, by inhibiting the activity of the enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme. Accumulating evidence suggests that the use of statins lowers the risk of dementia, most likely via amyloid-related mechanisms (Jick et al., Reference Jick, Zornberg, Jick, Seshadri and Drachman2000; Fassbender et al., Reference Fassbender2001; Pedrini et al., Reference Pedrini, Carter, Prendergast, Petanceska, Ehrlich and Gandy2005). Statins may also improve endothelial homeostasis by increasing the accessibility of nitric oxide (Vaughan, Reference Vaughan2003), which may facilitate chemical messaging between cells.

Our findings indicated that hypertension was a risk factor for lower episodic memory capacity. A number of previous studies have linked high arterial blood pressure to increased risk of late-life dementia and cognitive decline (Knopman et al., Reference Knopman2001; van Dijk et al., Reference van Dijk2004; Whitmer et al., Reference Whitmer, Sidney, Selby, Johnston and Yaffe2005). Indeed, studies have reported that hypertension may increase the rate of cognitive decline both in patients with AD (Hanon et al., Reference Hanon, Seux, Lenoir, Rigaud and Forette2003) and in controls (Bellew et al., Reference Bellew, Pigeon, Stang, Fleischman, Gardner and Baker2004). However, other studies have indicated no significant association between hypertension and age-related decline in cognitive performance (Farmer et al., Reference Farmer1987, Reference Farmer, Kittner, Abbott, Wolz, Wolf and White1990; Scherr et al., Reference Scherr, Herbert, Smith and Evans1991; van Boxtel et al., Reference van Boxtel, Buntinx, Houx, Metsemakers, Knotterus and Jolles1998). With respect to our own findings pertaining to hypertension, high blood pressure may cause cerebrovascular disease (particularly ischemia), including relatively minor but chronic disturbances in cerebral perfusion, producing unfavorable effects on brain cell metabolism (Elias et al., Reference Elias, Wolf, D'Agostino, Cobb and White1993). These changes may increase the likelihood that individuals with incipient AD pathology will express symptoms of dementia, including cognitive decline. Hypertension may also accelerate the AD process directly (Skoog and Gustafson, Reference Skoog and Gustafson2003), insofar as similar biological mechanisms may be involved in the pathogenesis of both hypertension and AD.

In summary, we have noted here that, in our cohort (Rodrigues et al., Reference Rodrigues2008) age, beta amyloid concentration and hypertension were negatively associated with episodic memory function, whereas education and statin use had positive associations with episodic memory. A relationship between endogenous estrogen and memory functioning was not evident. In future, additional insight will be gained from extended longitudinal investigations of similar cohorts, employing a wider range of cognitive and functional assessments in enriched groups of individuals who are at increased risk of prodromal AD. Further, although a wealth of literature exists on the relationship between reproductive hormones and cognitive decline, AD risk and AD pathogenesis, the precise role of estrogen still remains unclear. This is reiterated in the controversy that exists concerning the putative benefits of hormone replacement therapy for improving cognitive capacity and as a therapeutic for AD (for recent review and meta analysis, see Hogervorst et al., Reference Hogervorst, Yaffe, Richards and Huppert2009). It is clear that in future large clinical studies which control for a number of relevant factors (as adumbrated herein) are required to address some of the discrepancies in the extant literature (Manly et al., Reference Manly2000; Schupf et al., Reference Schupf2003).

Conflict of interest

None.

References

Alexopoulos, G. S., Young, R. C. and Meyers, B. S. (1993). Geriatric depression: age of onset and dementia. Biological Psychiatry, 34, 141–145.CrossRefGoogle ScholarPubMed
Barron, A. M., Fuller, S. J., Verdile, G. and Martins, R. N. (2006a). Reproductive hormones modulate oxidative stress in Alzheimer's disease. Antioxidants and Redox Signaling, 8, 2047–2059.CrossRefGoogle ScholarPubMed
Barron, A. M., Verdile, G. and Martins, R. N. (2006b). Gonadotropins: potential targets for preventative and therapeutic interventions in Alzheimer's disease. Future Neurology, 1, 189–202.Google Scholar
Bellew, K. M., Pigeon, J. G., Stang, P. E., Fleischman, W., Gardner, R. M. and Baker, W. W. (2004). Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer's Disease and Associated Disorders, 18, 208–213.Google ScholarPubMed
Buckwalter, J. G., Sobel, E., Dunn, M. E., Diz, M. M. and Henderson, V. W. (1993). Gender differences on a brief measure of cognitive functioning in Alzheimer's disease. Archives of Neurology, 50, 757–760.Google Scholar
Burkhardt, M. S. et al. (2004). Estrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4. Journal of Alzheimer's Disease, 6, 221–228.Google Scholar
Collie, A. and Maruff, P. (2000). The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment. Neuroscience and Biobehavioral Reviews, 24, 365–374.Google Scholar
Devanand, D. P. et al. (1996). Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Archives of General Psychiatry, 53, 175–182.Google Scholar
Drake, E. B. et al. (2000). Associations between circulating sex steroid hormones and cognition in normal elderly women. Neurology, 54, 599–603.Google Scholar
Elias, M. F., Wolf, P. A., D'Agostino, R. B., Cobb, J. and White, L. R. (1993). Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. American Journal of Epidemiology, 138, 353–364.CrossRefGoogle ScholarPubMed
Evans, D. A. et al. (1997). Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. JAMA, 277, 822–824.Google Scholar
Evans, D. A. et al. (2003). Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Archives of Neurology, 60, 185–189.CrossRefGoogle Scholar
Farmer, M. E. et al. (1987). Blood pressure and cognitive performance: the Framingham Study. American Journal of Epidemiology, 126, 1103–1114.CrossRefGoogle ScholarPubMed
Farmer, M. E., Kittner, S. J., Abbott, R. D., Wolz, M. M., Wolf, P. A. and White, L. R. (1990). Longitudinally measured blood pressure, antihypertensive medication use, and cognitive performance: the Framingham Study. Journal of Clinical Epidemiology, 43, 475–480.Google Scholar
Fassbender, K. et al. (2001). Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proceedings of the National Academy of Sciences of the USA, 98, 5856–5861.Google Scholar
Gatz, M., Svedberg, P., Pedersen, N. L., Mortimer, J. A., Berg, S. and Johansson, B. (2001). Education and the risk of Alzheimer's disease: findings from the study of dementia in Swedish twins. Journals of Gerontology, Series B: Psychological Sciences and Social Sciences, 56, 292–300.Google Scholar
Gilman, S. (1997). Alzheimer's disease. Perspectives in Biology and Medicine, 40, 230–245.Google Scholar
Hanon, O., Seux, M. L., Lenoir, H., Rigaud, A. S. and Forette, F. (2003). Hypertension and dementia. Current Cardiology Reports, 5, 435–440.Google Scholar
Henderson, V. and Buckwalter, J. (1994). Cognitive deficits of men and women with Alzheimer's disease. Neurology, 44, 90–96.CrossRefGoogle ScholarPubMed
Hogervorst, E., Yaffe, K., Richards, M. and Huppert, F. A. (2009). Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Systematic Review, 1, CD003799.Google Scholar
Hoskin, E. K., Tang, M. X., Manly, J. J. and Mayeux, R. (2004). Elevated sex-hormone binding globulin in elderly women with Alzheimer's disease. Neurobiology of Aging, 25, 141–147.CrossRefGoogle ScholarPubMed
Jacobs, D. M. et al. (1998). Cognitive function in nondemented older women who took estrogen after menopause. Neurology, 50, 368–373.Google Scholar
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. and Drachman, D. A. (2000). Statins and the risk of dementia. Lancet, 356, 1627–1631.CrossRefGoogle ScholarPubMed
Jorm, A. F. et al. (1991). Psychiatric history and related exposures as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. International Journal of Epidemiology, 20 (Suppl. 2), S43–S47.Google Scholar
Judd, L. L. and Akiskal, H. S. (2000). Delineating the longitudinal structure of depressive illness: beyond clinical subtypes and duration thresholds. Pharmacopsychiatry, 33, 3–7.Google Scholar
Judd, L. L. et al. (2000). Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? American Journal of Psychiatry, 157, 1501–1504.CrossRefGoogle Scholar
Kampen, D. L. and Sherwin, B. B. (1994). Estrogen use and verbal memory in healthy postmenopausal women. Obstetrics and Gynecology, 83, 979–983.CrossRefGoogle ScholarPubMed
Knopman, D. et al. (2001). Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology, 56, 42–48.Google Scholar
Kral, V. A. (1983) The relationship between senile dementia (Alzheimer type) and depression. Canadian Journal of Psychiatry, 28, 304–306.CrossRefGoogle ScholarPubMed
Manly, J. J. et al. (2000). Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology, 54, 833–837.Google Scholar
McEwen, B. S. (2001). Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Annals of the New York Academy of Sciences, 933, 265–277.Google Scholar
Ott, A. et al. (1995). Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam Study. BMJ, 310, 970–973.Google Scholar
Pedrini, S., Carter, T. L., Prendergast, G., Petanceska, S., Ehrlich, M. E. and Gandy, S. (2005). Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLOS Medicine, 2, 69–78.Google Scholar
Phillips, S. M. and Sherwin, B. B. (1992). Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology, 17, 485–495.Google Scholar
Qiu, C., Backman, L., Winblad, B., Aguero-Torres, H. and Fratiglioni, L. (2001). The influence of education on clinically diagnosed dementia: incidence and mortality data from the Kungsholmen Project. Archives of Neurology, 58, 2034–2039.Google Scholar
Ravaglia, G. et al. (2002). Education, occupation, and prevalence of dementia: findings from the Conselice study. Dementia and Geriatric Cognitive Disorders, 14, 90–100.Google Scholar
Remy, F., Mirrashed, F., Campbell, B. and Richter, W. (2005). Verbal episodic memory impairment in Alzheimer's disease: a combined structural and functional MRI study. Neuroimage, 25, 253–266.Google Scholar
Rodrigues, M. A. et al. (2008). Gonadotropins and cognition in older women. Journal of Alzheimer's Disease, 13, 267–274.Google Scholar
Scherr, P. A., Herbert, L. E., Smith, L. A. and Evans, D. A. (1991). Relation of blood pressure to cognitive function in the elderly. American Journal of Epidemiology, 134, 1303–1315.Google Scholar
Schupf, N. et al. (2003). Onset of dementia is associated with age at menopause in women with Down's syndrome. Annals of Neurology, 54, 433–438.CrossRefGoogle ScholarPubMed
Senanarong, V. et al. (2002). Endogenous estradiol in elderly individuals: cognitive and noncognitive associations. Archives of Neurology, 59, 385–389.Google Scholar
Sherwin, B. B. (2002). Randomized clinical trials of combined estrogen-androgen preparations: effects on sexual functioning. Fertility and Sterility, 77 (Suppl. 4), S49–S54.CrossRefGoogle ScholarPubMed
Sherwin, B. B. (2003). Estrogen and cognitive functioning in women. Endocrine Reviews, 24, 133–151.CrossRefGoogle ScholarPubMed
Skoog, I. and Gustafson, D. (2003). Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurological Research, 25, 675–680.Google Scholar
Tsolaki, M. et al. (2005). Serum estradiol, progesterone, testosterone, FSH and LH levels in postmenopausal women with Alzheimer's dementia. Hellenic Journal of Nuclear Medicine, 8, 39–42.Google ScholarPubMed
van Boxtel, M. P., Buntinx, F., Houx, P. J., Metsemakers, J. F., Knotterus, A. and Jolles, J. (1998). The relation between morbidity and cognitive performance in a normal aging population. Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 53, M147–M154.CrossRefGoogle Scholar
van Dijk, E. J. et al. (2004). The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension, 44, 625–630.Google Scholar
van Duijn, C. M., Stijnen, T. and Hofman, A. (1991). Risk factors for Alzheimer's disease: overview of the EURODEM collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. International Journal of Epidemiology, 20 (Suppl. 2), S4–S12.CrossRefGoogle ScholarPubMed
Vaughan, C. J. (2003). Prevention of stroke and dementia with statins: effects beyond lipid lowering. American Journal of Cardiology, 91, 23B–29B.CrossRefGoogle ScholarPubMed
Wells, K. B. et al. (1989). The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA, 262, 914–919.Google Scholar
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C. and Yaffe, K. (2005). Midlife cardiovascular risk factors and risk of dementia in late life. Neurology, 64, 277–281.Google Scholar
Wolf, O. T. and Kirschbaum, C. (2002). Endogenous estradiol and testosterone levels are associated with cognitive performance in older women and men. Hormones and Behavior, 41, 259–266.Google Scholar
Yaffe, K., Lui, L.-Y., Grady, D., Cauley, J., Kramer, J. and Cummings, S. R. (2000). Cognitive decline in women in relation to non-protein-bound estradiol concentrations. Lancet, 356, 708–712.Google Scholar
Yoshitake, T. et al. (1995). Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology, 45, 1161–1168.CrossRefGoogle Scholar